Literature DB >> 12907392

The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins.

June Harland1, Paul Dunn, Euan Cameron, Joe Conner, S Moira Brown.   

Abstract

The replicative ability of ICP34.5-null herpes simplex virus (HSV) is cell type and state dependent. In certain cells, ICP34.5 interacts with protein phosphatase 1 to preclude host cell protein synthesis shutoff by dephosphorylation of the eukaryotic initiation factor eIF-2alpha. However, host cell shutoff is not induced by ICP34.5-null HSV in most cells, irrespective of type and state. In general, dividing cells support replication of ICP34.5-null HSV; nondividing cells cannot. Previously the authors showed that ICP34.5 binds to proliferating cell nuclear antigen (PCNA), a protein necessary for cellular DNA replication and repair. Here the authors demonstrate that (1) the interaction between ICP34.5 and PCNA involves two regions of the virus protein; (2) ICP34.5 forms a complex with HSV replication proteins that is DNA binding; (3) at early times in infection, ICP34.5 colocalizes with PCNA and HSV replication proteins in cell nuclei, before accumulating in the cytoplasm; and (4) ICP34.5 is a virion protein. In light of ongoing clinical trials assessing the safety and efficacy of ICP34.5-null HSV, it is vital that the roles of ICP34.5 in HSV replication are understood. The authors propose that in nondividing cells, ICP34.5 is required to switch PCNA from repair to replication mode, a prerequisite for the initiation of HSV replication.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907392     DOI: 10.1080/13550280390218788

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  63 in total

1.  Identification of an African swine fever virus gene with similarity to a myeloid differentiation primary response gene and a neurovirulence-associated gene of herpes simplex virus.

Authors:  M D Sussman; Z Lu; G Kutish; C L Afonso; P Roberts; D L Rock
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Monoclonal antibodies against herpes simplex virus type 1-infected nuclei defining and localizing the ICP8 protein, 65K DNA-binding protein and polypeptides of the ICP35 family.

Authors:  P Schenk; S Pietschmann; H Gelderblom; G Pauli; H Ludwig; P Schenck
Journal:  J Gen Virol       Date:  1988-01       Impact factor: 3.891

3.  A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function.

Authors:  I Mohr; Y Gluzman
Journal:  EMBO J       Date:  1996-09-02       Impact factor: 11.598

4.  Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant.

Authors:  B P Randazzo; M G Bhat; S Kesari; N W Fraser; S M Brown
Journal:  J Invest Dermatol       Date:  1997-06       Impact factor: 8.551

5.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

6.  The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase.

Authors:  B He; M Gross; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

7.  The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.

Authors:  V Papanastassiou; R Rampling; M Fraser; R Petty; D Hadley; J Nicoll; J Harland; R Mabbs; M Brown
Journal:  Gene Ther       Date:  2002-03       Impact factor: 5.250

8.  Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy.

Authors:  E A McKie; S M Brown; A R MacLean; D I Graham
Journal:  Neuropathol Appl Neurobiol       Date:  1998-10       Impact factor: 8.090

9.  Characterization of the herpes simplex virus type 1 strain 17+ neurovirulence gene RL1 and its expression in a bacterial system.

Authors:  E A McKie; R G Hope; S M Brown; A R MacLean
Journal:  J Gen Virol       Date:  1994-04       Impact factor: 3.891

10.  Purification of the herpes simplex virus type 1 65-kilodalton DNA-binding protein: properties of the protein and evidence of its association with the virus-encoded DNA polymerase.

Authors:  M L Gallo; D H Jackwood; M Murphy; H S Marsden; D S Parris
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

View more
  23 in total

1.  Comprehensive characterization of extracellular herpes simplex virus type 1 virions.

Authors:  Sandra Loret; Ginette Guay; Roger Lippé
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

2.  Herpes simplex virus type 1 strain HSV1716 grown in baby hamster kidney cells has altered tropism for nonpermissive Chinese hamster ovary cells compared to HSV1716 grown in vero cells.

Authors:  Joe Conner; Frazer J Rixon; S Moira Brown
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.

Authors:  Ryuichi Kanai; Cecile Zaupa; Donatella Sgubin; Slawomir J Antoszczyk; Robert L Martuza; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.

Authors:  Chelsea Bolyard; Ji Young Yoo; Pin-Yi Wang; Uksha Saini; Kellie S Rath; Timothy P Cripe; Jianying Zhang; Karuppaiyah Selvendiran; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

5.  Characterization of the subcellular localization of herpes simplex virus type 1 proteins in living cells.

Authors:  Junji Xing; Shuai Wang; You Li; Hong Guo; Lei Zhao; Weiwei Pan; Fusen Lin; Huifang Zhu; Lei Wang; Meili Li; Lin Wang; Chunfu Zheng
Journal:  Med Microbiol Immunol       Date:  2010-10-15       Impact factor: 3.402

6.  Resistance of mRNA translation to acute endoplasmic reticulum stress-inducing agents in herpes simplex virus type 1-infected cells requires multiple virus-encoded functions.

Authors:  Matthew Mulvey; Carolina Arias; Ian Mohr
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

7.  Functional genomic analysis of herpes simplex virus type 1 counteraction of the host innate response.

Authors:  Tracy Jo Pasieka; Tracey Baas; Victoria S Carter; Sean C Proll; Michael G Katze; David A Leib
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

8.  Herpes simplex virus 2 expresses a novel form of ICP34.5, a major viral neurovirulence factor, through regulated alternative splicing.

Authors:  Shuang Tang; Nini Guo; Amita Patel; Philip R Krause
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

9.  Replication of herpes simplex virus 1 depends on the gamma 134.5 functions that facilitate virus response to interferon and egress in the different stages of productive infection.

Authors:  Xianghong Jing; Melissa Cerveny; Kui Yang; Bin He
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 10.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Authors:  Z Sheng Guo; Stephen H Thorne; David L Bartlett
Journal:  Biochim Biophys Acta       Date:  2008-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.